Unknown

Dataset Information

0

Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients.

ABSTRACT: Risk stratification of multiple myeloma (MM) at diagnosis is critical. We examined the ability of hematopoietic indices including mean corpuscular volume (MCV), hemoglobin (Hgb), and platelet (Plt) to predict outcomes. This was a retrospective study of patients treated at Mayo Clinic between January 2004 and April 2018. We incorporated three variables (Hgb??96?fL), assigning a score of 1 to each. We identified 1540 newly diagnosed MM patients, of whom 707 (46%) had a score of 0, 513 (33%) had a score of 1, 260 (17%) had a score of 2, and 60 (4%) had a score of 3. The score risk stratified patients into four groups with differing survivals. The median PFS was 32.3 months for score 0, 24.8 months for score 1, 21.7 months for score 2, and 18.3 months for score 3, for P

SUBMITTER: Al Saleh AS 

PROVIDER: S-EPMC7377299 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Risk stratification of multiple myeloma (MM) at diagnosis is critical. We examined the ability of hematopoietic indices including mean corpuscular volume (MCV), hemoglobin (Hgb), and platelet (Plt) to predict outcomes. This was a retrospective study of patients treated at Mayo Clinic between January 2004 and April 2018. We incorporated three variables (Hgb < 10 g/dL, Plt < 150 × 10<sup>9</sup> /L, and MCV > 96 fL), assigning a score of 1 to each. We identified 1540 newly diagnosed MM patients, o  ...[more]

Similar Datasets

Unknown Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation.
| S-EPMC4851188 | biostudies-literature
Unknown The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution.
| S-EPMC4799960 | biostudies-other
Unknown A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
| S-EPMC7214253 | biostudies-literature
Transcriptomics Expression data from BM-CD138+, obtained from newly diagnosed Multiple Myeloma patients
2014-12-23 | GSE58133 | GEO
Transcriptomics Expression data of newly diagnosed multiple myeloma and extramedullary myeloma
2023-03-01 | GSE147841 | GEO
Unknown Daratumumab in untreated newly diagnosed multiple myeloma.
| S-EPMC6928545 | biostudies-literature
Unknown Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.
| S-EPMC5571752 | biostudies-other
Transcriptomics Expression data from BM-CD138+, obtained from newly diagnosed Multiple Myeloma patients
2014-12-23 | E-GEOD-58133 | biostudies-arrayexpress
Unknown Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma.
| S-EPMC6560628 | biostudies-literature
Unknown Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma.
| S-EPMC5058940 | biostudies-literature